• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21797 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis, homozygous F508del mutation in the CFTR gene, 2-5 years) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis, 1 to < 2 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis in children aged 2 to 5 years) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Lower Urinary Tract Symptoms - epidemiology and results from LUTS project Funen on implementation of a clinical guideline in general practice]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Lower respiratory tract infections of a viral origin in the paediatric population: systematic review of Spanish literature]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Low-intensity ultrasound for the treatment of fractures]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Low-intensity pulsed ultrasound for the treatment of pseudarthrosis]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Low-dose computed tomography screening for lung cancer]
1999     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Low-back pain: frequency, management and prevention from an HTA perspective]
2002     Basque Office for Health Technology Assessment (OSTEBA) [Low molecular weight heparins versus traditional heparins in thromboembolic diseases]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Low density lipoprotein apheresis as adjuvant treatment for familial hypercholesterolaemia]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lorlatinib (NSCLC) - benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lonoctocog alfa (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Longevity of dental amalgam in comparison to composite materials]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [Long-term safety and stability of refractive surgeries in myopia]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Long-acting insulin analogues in the treatment of diabetes mellitus type 2]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Long-acting insulin analogues in the treatment of diabetes mellitus type 1]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Long term substitution treatment (maintenance treatment) of opioid dependent persons]
2009     Finnish Office for Health Care Technology Assessment (Finohta) [Long term sensors for measuring blood sugar]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Long term institutional or residential treatment of patients with substance abuse compared to short-term outpatient treatment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lonapegsomatropin (growth hormone deficiency) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lonafarnib (Hutchinson-Gilford progeria syndrome or progeroid laminopathy) - Benefit assessment according to §35a SGB V [1], Sentence 11]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lomitapide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lomitapide - Addendum to Commission A15-23]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Localized prostate cancer: effectiveness and safety of treatment options]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Localized and disseminated stages of Lyme disease: from diagnosis to treatment, report in support of the diagnosis and treatment decision support tools]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Local injection therapy with bulking agents for faecal incontinence]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lixisenatide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2007     Health Council of the Netherlands Gezondheidsraad (GR) [Living donor list exchange: an addition to the Dutch living kidney donor programme?]
2010     Committee for New Health Technology Assessment (CNHTA) [Liver cancer prognostic marker(OncoHepa)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Literature search and evidence assessment to examine the effects of regulations for minimum volumes (acc. to §6 [5], line 2 of the directive on outpatient treatment in hospitals acc. to §116b Social Code Book V) - Rapid report]
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Literature review on efficacy and safety of ultraviolet light and ozone for surface disinfection (Update)]
2011     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Literature review of organisational and patient aspects in HTA]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Literature bibliographic search protocols adapting them to the different search outputs]
2012     Norwegian Knowledge Centre for the Health Services (NOKC) [List size and quality of care among GPs within The Regular General Practitioner Scheme]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisdexamfetamine (ADHD) - Benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisdexamfetamine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Liraglutide in obese and overweight patients]
2008     The Regional Health Technology Assessment Centre (HTA-centrum) [Liquid-based cytology for screening of precursors of cervical cancer]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2020     Canary Health Service [Liquid biopsy for the detection of ovarian or endometrial cancer in samples taken from the Pap smear: PapSEEK]
2008     Committee for New Health Technology Assessment (CNHTA) [Liqui-Prep TM]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Liposuction for the removal of subcutaneous (large) lipomas]
2021     Norwegian Institute of Public Health (NIPH) [Liposuction (lipectomy) for the treatment of fat accumulation caused by chronic lymphoedema]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Liposomal combination of cytarabine and daunorubicin (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Lipogems® System for autologous adipose tissue-derived mesenchymal stem cells transfer in orthopedic conditions]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Lipoedema – diagnosis, treatment, and experiences]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Lipid metabolism disorders: review of the indications of fat free dietetic products and nutritional alternatives with regularly consumed foodstuffs]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Linear accelerator radiosurgery for trigeminal neuralgia]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linagliptin - Re-assessment of benefit according to § 35a, Para. 5b, Social Code Book V (dossier assessment)]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linaclotide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Levonorgestrel-releasing intrauterine device (IUD) for patients with hypermenorrhea]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Addendum to Commission A21-12]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Levels of medical intervention -- levels of care]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Levels of care: norms and quality standards]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Leukotriene receptor antagonists in patients with asthma]
2009     The Swedish Council on Health Technology Assessment (SBU) [Leukocytapheresis in inflammatory bowel disease (primarily ulcerative colitis)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (prophylaxis of cytomegalovirus reactivation and disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Lenvatinib for iodine-refractory differentiated thyroid cancer]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma): benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (hepatocellular carcinoma) - Addendum to Commission A18-57]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [LEG TEST. Multi centre testing of the Lively Legs program for promoting compliance with compression therapy and prescribed exercise in leg ulcer patients]
2018     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Left ventricular assist device (LVAD) as destination therapy]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (hepatitis C) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (Addendum to Commission A14-44)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Lecanemab in Alzheimer’s Disease]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lead extraction of pacemaker or implantable cardiac defibrillator leads using laser excimer]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [LDL-Apheresis in familial hypercholesterolemia and hypertriglyceridemia]
2023     Center for Drug Evaluation (CDE) [Latest trend in consumption and utilization of schedule I and II controlled drugs - a nationwide population-based data in Taiwan
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (primary open-angle glaucoma and ocular hypertension) – Addendum to Commission A22-129]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (glaucoma) - Benefit assessment according to §35a Social Code Book V]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Last trends in genetic therapy]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lasmiditan (migraine) – Benefit assessment according to §35a Social Code Book V]
2011     The Swedish Council on Health Technology Assessment (SBU) [Laser-induced interstitial thermal therapy for liver metastases]
2013     Haute Autorite de sante (HAS) [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Laser treatment for benign prostatic hyperplasia. Proposal of assessment indicators]
2009     The Swedish Council on Health Technology Assessment (SBU) [Laser technology for removal of caries]
2021     Andalusian Health Technology Assessment Area (AETSA) [Laser interstitial thermal therapy for patients with refractory epilepsy: safety and effectiveness. A systematic review]
1995     Basque Office for Health Technology Assessment (OSTEBA) [Laser excimer in ophthalmology]